Grifols SA
MAD:GRF
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.898
15.455
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Grifols SA
Grifols SA
Income from Continuing Operations
Grifols SA
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Grifols SA
MAD:GRF
|
Income from Continuing Operations
€180.7m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Oryzon Genomics SA
MAD:ORY
|
Income from Continuing Operations
-€3.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Pharma Mar SA
MAD:PHM
|
Income from Continuing Operations
€622k
|
CAGR 3-Years
-79%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-27%
|
|
|
Biotechnology Assets SA
MAD:BST
|
Income from Continuing Operations
-€3.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Grifols SA
Glance View
Grifols SA, a global healthcare giant based in Barcelona, Spain, has carved its niche in the world through its pioneering work with plasma-derived medicines. Founded in 1940, the company has grown from a small family business into one of the world leaders in the production and development of biopharmaceuticals, particularly those derived from human plasma. Grifols operates a robust network of plasma donation centers, primarily in the United States, where it sources its primary raw material. The company's meticulous process involves collecting plasma from donors, which is then transported to sophisticated manufacturing facilities. Here, this vital fluid is fractionated into various components used to create life-saving treatments. These treatments address a spectrum of conditions, including hemophilia, immune deficiencies, and neurological issues, highlighting Grifols' integral role in advancing healthcare solutions. Grifols' business model is astutely designed to capitalize on the high demand for plasma-derived therapies, ensuring a steady stream of revenue. By vertically integrating its operations—from plasma collection through to product distribution—Grifols maintains stringent quality control and operational efficiency, driving down costs and enhancing margins. The company's segmentation includes Bioscience, which focuses on plasma-derived therapies; Diagnostic, which involves manufacturing tools and reagents for clinical analysis; and Hospital, which manages pharmacy and healthcare logistics products. Furthermore, the company has ventured into bio supplies, supplying biological materials for non-therapeutic use to life-science research. With a deep commitment to innovation and strategic acquisitions, Grifols stays ahead in the competitive biopharmaceutical landscape while fostering a direct link between donor generosity and patient needs, ensuring that its growth story has a profound impact on global health.
See Also
What is Grifols SA's Income from Continuing Operations?
Income from Continuing Operations
180.7m
EUR
Based on the financial report for Dec 31, 2023, Grifols SA's Income from Continuing Operations amounts to 180.7m EUR.
What is Grifols SA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-21%
Over the last year, the Income from Continuing Operations growth was -33%. The average annual Income from Continuing Operations growth rates for Grifols SA have been -38% over the past three years , -21% over the past five years .
You don't have any saved screeners yet
